Anales de la RANM

131 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 PREVENCIÓN DE LA ERC Ortiz A, et al. An RANM. 2023;140(02):125 - 132 8. Clark A, Jit M, Warren-Gash C et al. Global, re- gional, and national estimates of the population at increased risk of severe COVID-19 due to un- derlying health conditions in 2020: a modelling study. Lancet Glob Heal. 2020; 8: e1003–e1017 9. Jager KJ, Kramer A, Chesnaye NC et al. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int. 2020; 98: 1540-1548. 10. Ortiz A, Roger M, Jiménez VM et al. RI- CORS2040: the need for collaborative research in chronic kidney disease. Clin Kidney J. 2021; 15(3): 372-387. 11. Boenink R, Astley ME, Huijben JA et al. The ERA Registry Annual Report 2019: summary and age comparisons. Clin Kidney J. 2021; 15(3): 452-472. 12. Vanholder R, Annemans L, Bello AK et al. Fighting the unbearable lightness of neglecting kidney health: the decade of the kidney. Clin Kidney J. 2021; 14(7): 1719-1730. 13. Vanholder R, Agar J, Braks M et al. The Eu- ropean Green Deal and nephrology: a call for action by the European Kidney Health Allian- ce. Nephrol Dial Transplant. 2023; 38(5): 1080-1088. doi: 10.1093/ndt/gfac160. PMID: 35481547. 14. Heerspink HJL, Stefánsson BV, Correa-Rotter R et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020; 383(15): 1436-1446. 15. The EMPA-KIDNEY Collaborative Group; He- rrington WG, Staplin N, Wanner C et al. Empa- gliflozin in patients with chronic kidney disea- se. N Engl J Med. 2023; 388(2): 117-127. 16. Anker SD, Butler J, Filippatos G et al. Empagli- flozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021; 385(16): 1451- 1461. 17. Packer M, Anker SD, Butler J et al. Cardiovas- cular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020; 383: 1413- 1424. 18. Solomon SD, McMurray JJV, Claggett B et al. Dapagliflozin in heart failure with mildly re- duced or preserved ejection fraction. N Engl J Med. 2022; 387: 1089-1098. 19. McMurray JJV, Solomon SD, Inzucchi SE et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381: 1995-2008. 20. Perkovic V, Jardine MJ, Neal B et al. Canagliflo- zin and renal outcomes in type 2 diabetes and ne- phropathy. N Engl J Med. 2019; 380: 2295-2306. 21. Agarwal R, Filippatos G, Pitt B et al; FIDELIO- DKD and FIGARO-DKD investigators. Cardio- vascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022; 43(6): 474-484. 22. Levin A, Perkovic V, Wheeler DC et al. Empa- gliflozin and cardiovascular and kidney outco- mes across KDIGO risk categories: Post hoc analysis of a randomized, double-blind, place- bo-controlled, multinational trial. Clin J Am Soc Nephrol. 2020; 15: 1433-1444. 23. https://academic.oup.com/ckj/advance-article/ doi/10.1093/ckj/sfad082/7199787 24. Li PKT, Garcia-Garcia G, Lui SF et al. Kidney health for everyone everywhere-from preven- tion to detection and equitable access to care. Kidney Int. 2020; 97: 226-232. 25. Levey AS, Schoolwerth AC, Burrows NR, Williams DE, Stith KR, McClellan W. Com- prehensive public health strategies for pre- venting the development, progression, and complications of CKD: Report of an expert panel convened by the Centers for Disea- se Control and Prevention. Am J Kidney Dis. 2009; 53: 522-535. 26. Kelly JT, Su G, Zhang L et al. Modifiable lifes- tyle factors for primary prevention of CKD: a systematic review and meta-analysis. J Am Soc Nephrol. 2021; 32: 239-253. 27. Paterson EN, Neville CE, Wallace SM et al. Die- tary patterns associated with renal impairment in the Northern Ireland Cohort for the Longi- tudinal Study of Ageing (NICOLA). Eur J Nutr. 2021; 60: 4045-4054. 28. Staessen JA, Janssens S, Van de Werf F. Do cli- nical trial data suggest a role for SGLT2-inhibi- tors in primary prevention of heart failure and chronic kidney disease? Int J Cardiol Cardio- vasc Risk Prev. 2021; 10: 200100. doi:10.1016/J. IJCRP.2021.200100. 29. Wiviott SD, Raz I, Bonaca MP et al. Dapagli- flozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380: 347-357. 30. Neal B, Perkovic V, Mahaffey KW et al. Cana- gliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377: 644-657. 31. Wanner C, Inzucchi SE, Lachin JM et al. Empa- gliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016; 375: 323- 334. 32. Mosenzon O, Wiviott SD, Cahn A et al. Effects of dapagliflozin on development and progres- sion of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocri- nol. 2019; 7: 606-617. 33. Mosenzon O, Raz I, Wiviott SD et al. Dapagli- flozin and prevention of kidney disease among patients with type 2 diabetes: Post hoc analyses from the DECLARE-TIMI 58 Trial. Diabetes Care. 2022; 45: 2350-2359. 34. Bosch C, Carriazo S, Soler MJ, Ortiz A, Fernán- dez-Fernández B. Tirzepatide and prevention of chronic kidney disease. Clin Kidney J. 2022; 16(5):797-808. doi:10.1093/CKJ/SFAC274 35. Ortiz A, Ferro CJ, Balafa O et al. Mineralocorti- coid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. Nephrol Dial Transplant. 2023; 38(1): 10-25. 36. Kress S, Bramlage P, Holl RW et al. Validation of a risk prediction model for early chronic kidney disease in patients with type 2 diabe- tes: Data from the German/Austrian diabe- tes prospective follow-up registry. Diabetes Obes Metab. 2023; 25(3):776-784. doi:10.1111/ DOM.14925